Drugs / V158866
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01634529 | Mar → Jul 2011 | — | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01748695 | Jun 2013 → Jul 2015 | — | Brigham and Women's Hospital | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V158866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01748695 ↗ |
| Action | Inhibit | “V158866 inhibits fatty acid amide hydrolase (FAAH )” NCT01634529 ↗ |
| Route | Oral | “single and multiple ascending oral doses of V158866” NCT01634529 ↗ |
| Target | FAAH | “V158866 inhibits fatty acid amide hydrolase (FAAH )” NCT01634529 ↗ |